Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | CHIEF SCIENTIFIC OFFICER | September 18, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,712 |
Reported balance
After 2026-09-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-18 · Exercise / conversion · Acquired 3,750 · Balance 13,712 F1: The reported total includes 444 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). |
| Common StockSEC Table I · non-derivative | Direct | 12,367 |
Reported balance
After 2026-09-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-18 · Tax withholding · Disposed 1,345 · Balance 12,367 F2: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Expires 2027-09-18 | Direct | 3,750 |
Reported balance
After 2026-09-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-18 · Exercise / conversion · Disposed 3,750 · Balance 3,750 F3: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on September 18, 2024, subject to the reporting person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported total includes 444 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
F2: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F3: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F4: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on September 18, 2024, subject to the reporting person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 20:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-26-000004 · form4-09222026_080918.xml · derivative · entry 3 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on September 18, 2024, subject to the reporting person's continued service through each vesting date. Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 20:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,345 | $15.34 | $20,632.30 |
DisclosureSEC source: 0001992979-26-000004 · form4-09222026_080918.xml · nonDerivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,367 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 20:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-26-000004 · form4-09222026_080918.xml · nonDerivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes 444 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · derivative · entry 8 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-03-02 F6 · derivative.exercise_date: 1/48 of the total option award shall vest monthly, subject to the reporting person's continued service through each vesting date, with the first tranche vesting on April 1, 2026. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · derivative · entry 7 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total award annually, with the first tranche vesting on March 1, 2027, subject to continued service through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 2,843 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · derivative · entry 6 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,532 Underlying: Common Stock · 2,843 shares Expires 2029-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 2, 2026, subject to continued service through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,170 | $20.55 | $24,043.50 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 4 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,518 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,843 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 3 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · derivative · entry 5 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 1,125 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 463 | $20.47 | $9,477.61 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,845 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:49 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 7,925 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001992979-25-000006 · form4-12292025_091224.xml · derivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,925 Underlying: Common Stock · 7,925 shares Expires 2035-12-23 F1 · derivative.exercise_date: 1/48 of the total option award shall vest monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 08:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 17,000 | $0.80 | $13,606.80 |
DisclosureSEC source: 0001992979-25-000004 · form4-10162025_121041.xml · nonDerivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,832 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7932 to $0.8015, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 17:01 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-25-000003 · form4-09222025_090937.xml · derivative · entry 3 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 37,500 shares Expires 2027-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests annually as to 1/4th of the total award beginning on September 18, 2024, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 17:01 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 13,417 | $0.90 | $12,075.30 |
DisclosureSEC source: 0001992979-25-000003 · form4-09222025_090937.xml · nonDerivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,832 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 17:01 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001992979-25-000003 · form4-09222025_090937.xml · nonDerivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 113,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010384 · form4-04082025_080457.xml · derivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,750 Underlying: Common Stock · 113,750 shares Expires 2029-03-02 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 2, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy) · Derivative | 122,500 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-25-010384 · form4-04082025_080457.xml · derivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,500 Underlying: Common Stock · 122,500 shares Expires 2035-04-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on May 4, 2025, with 100% of the award being vested and exercisable on April 4, 2029, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:34 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006696 · form4-03042025_110331.xml · derivative · entry 3 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 11,250 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:34 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 4,621 | $1.59 | $7,347.39 |
DisclosureSEC source: 0001415889-25-006696 · form4-03042025_110331.xml · nonDerivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,749 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:34 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006696 · form4-03042025_110331.xml · nonDerivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023745 · form4-09202024_080944.xml · derivative · entry 3 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires 2027-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests annually as to 1/4th of the total award beginning on September 18, 2024, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 13,380 | $3.95 | $52,851.00 |
DisclosureSEC source: 0001415889-24-023745 · form4-09202024_080944.xml · nonDerivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,120 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023745 · form4-09202024_080944.xml · nonDerivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007184 · form4-03072024_090326.xml · derivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 60,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001415889-24-007184 · form4-03072024_090326.xml · derivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 16:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049943 · doc4.xml · derivative · entry 2 Gerber Hans-Peter · CIK 0001992979 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-09-18 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests annually as to 1/4th of the total award beginning on September 18, 2024, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 16:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001209191-23-049943 · doc4.xml · derivative · entry 1 Gerber Hans-Peter · CIK 0001992979 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-09-18 F1 · derivative.exercise_date: 25% of the option award vests on September 18, 2024. The remainder vests ratably as to 1/48th of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.